Literature DB >> 7669593

High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.

C L Hanna1, F E McKinna, L B Williams, D Morrey, M Adams, M D Mason, T S Maughan.   

Abstract

We have conducted a retrospective study of high-dose folinic acid and 5-fluorouracil in 96 patients with advanced colorectal cancer. Patients received 200 mg m-2 (maximum 300-350 mg) folinic acid by infusion over 2 h followed by an i.v. bolus of 5-fluorouracil 400 mg m-2 then an infusion of 5-fluorouracil 600 mg m-2 over 22 h. This was repeated over the next 24 h. The schedule was given every 2 weeks for four cycles; thereafter patients with objective response continued to a maximum of eight cycles. The overall response rate was 10.6% in 85 evaluable patients. The median duration of response was 11 months. The median survival was 6 months. Toxicity was low, only one patient experiencing toxicity greater than WHO grade II (grade IV platelet toxicity). Diarrhoea, nausea, vomiting and mucositis also occurred but were mild and infrequent. Our low response rate may be related to factors such as patient characteristics or duration of treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669593      PMCID: PMC2033907          DOI: 10.1038/bjc.1995.409

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  4 in total

1.  High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.

Authors:  A De Gramont; M Krulik; J Cady; B Lagadec; J E Maisani; J P Loiseau; J D Grange; G Gonzalez-Canali; B Demuynck; C Louvet
Journal:  Eur J Cancer Clin Oncol       Date:  1988-09

2.  Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.

Authors:  M A Poon; M J O'Connell; H S Wieand; J E Krook; J B Gerstner; L K Tschetter; R Levitt; C G Kardinal; J A Mailliard
Journal:  J Clin Oncol       Date:  1991-11       Impact factor: 44.544

3.  A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas.

Authors:  P W Johnson; P I Thompson; M T Seymour; N P Deasy; R C Thuraisingham; M L Slevin; P F Wrigley
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

4.  Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?

Authors:  D I Jodrell; L S Murray; N S Reed; P A Canney; S B Kaye; J Cassidy
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

  4 in total
  3 in total

1.  Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

Authors:  M J Mackean; J Cassidy; D I Jodrell; J Paul; N S Reed; P A Canney; H Yosef; T Habeshaw; A G Robertson; A McInnes; C J Twelves
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

2.  Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients.

Authors:  Usman Arshad; Su-Arpa Ploylearmsaeng; Alexander Jetter; Max Taubert; Mats O Karlsson; Oxana Doroshyenko; Dorothee Langer; Edgar Schömig; Sabine Kunze; Semih A Güner; Roman Skripnichenko; Sami Ullah; Ulrich Jaehde; Uwe Fuhr
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-09       Impact factor: 3.333

3.  The Value of Restaging With Chest and Abdominal CT/MRI Scan After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.

Authors:  Guo-Chen Liu; Xu Zhang; E Xie; Xin An; Pei-Qiang Cai; Ying Zhu; Jing-Hua Tang; Ling-Heng Kong; Jun-Zhong Lin; Zhi-Zhong Pan; Pei-Rong Ding
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.